loading
Schlusskurs vom Vortag:
$5.28
Offen:
$5.22
24-Stunden-Volumen:
160.39K
Relative Volume:
0.63
Marktkapitalisierung:
$120.29M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-51.50M
KGV:
-20.96
EPS:
-0.25
Netto-Cashflow:
$-47.10M
1W Leistung:
-4.90%
1M Leistung:
-7.91%
6M Leistung:
-33.42%
1J Leistung:
-39.01%
1-Tages-Spanne:
Value
$5.06
$5.29
1-Wochen-Bereich:
Value
$5.03
$5.53
52-Wochen-Spanne:
Value
$4.61
$12.85

Outlook Therapeutics Inc Stock (OTLK) Company Profile

Name
Firmenname
Outlook Therapeutics Inc
Name
Telefon
(609) 619-3990
Name
Adresse
111 S. WOOD AVENUE, ISELIN, NJ
Name
Mitarbeiter
24
Name
Twitter
Name
Nächster Verdiensttermin
2024-08-14
Name
Neueste SEC-Einreichungen
Name
OTLK's Discussions on Twitter

Vergleichen Sie OTLK mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
OTLK 5.23 120.29M 0 -51.50M -47.10M -0.25
VRTX 450.37 115.43B 10.63B -479.80M -1.35B 13.33
REGN 748.00 82.04B 13.85B 4.65B 3.32B 35.06
ARGX 590.18 35.30B 1.86B -40.29M -1.28B -4.16
ALNY 246.61 32.04B 2.09B -332.26M 16.06M -4.14
BNTX 107.08 24.89B 3.30B -501.07M 1.03B 11.54

Outlook Therapeutics Inc Stock (OTLK) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2023-04-03 Eingeleitet Guggenheim Buy
2023-02-06 Eingeleitet Cantor Fitzgerald Overweight
2022-10-31 Eingeleitet BTIG Research Buy
2022-09-13 Eingeleitet Chardan Capital Markets Buy
2019-09-11 Eingeleitet Ladenburg Thalmann Buy
2019-05-16 Eingeleitet Oppenheimer Outperform
2019-04-22 Eingeleitet Ascendiant Capital Markets Buy
Alle ansehen

Outlook Therapeutics Inc Aktie (OTLK) Neueste Nachrichten

pulisher
Nov 19, 2024

Cadrenal Therapeutics Named Anticoagulation Therapy Company of the Year by Pharma Tech Outlook - PR Newswire

Nov 19, 2024
pulisher
Nov 18, 2024

(OTLK) Trading Signals - Stock Traders Daily

Nov 18, 2024
pulisher
Nov 15, 2024

Great Point Partners LLC Bolsters Position in Outlook Therapeuti - GuruFocus.com

Nov 15, 2024
pulisher
Nov 08, 2024

Learn to Evaluate (OTLK) using the Charts - Stock Traders Daily

Nov 08, 2024
pulisher
Nov 08, 2024

Repare Therapeutics Reports Q3 2024 Progress and Outlook - TipRanks

Nov 08, 2024
pulisher
Nov 07, 2024

Velan Capital Investment Management LP Increases Stake in Outloo - GuruFocus.com

Nov 07, 2024
pulisher
Nov 07, 2024

Unveiling Heron Therapeutics (HRTX) Q3 Outlook: Wall Street Estimates for Key Metrics - Yahoo Finance

Nov 07, 2024
pulisher
Nov 06, 2024

Aterian Investment Partners acquires Outlook Group to support growth - Packaging Gateway

Nov 06, 2024
pulisher
Nov 06, 2024

Outlook Therapeutics® to Present at the Guggenheim Healthcare Innovation Conference - GlobeNewswire

Nov 06, 2024
pulisher
Nov 06, 2024

Outlook Therapeutics CEO to Present at Guggenheim Healthcare Conference After EU Win | OTLK Stock News - StockTitan

Nov 06, 2024
pulisher
Nov 02, 2024

Breakeven On The Horizon For Outlook Therapeutics, Inc. (NASDAQ:OTLK) - Simply Wall St

Nov 02, 2024
pulisher
Oct 30, 2024

Outlook Therapeutics, Inc. (NASDAQ:OTLK) Receives Consensus Rating of "Buy" from Brokerages - MarketBeat

Oct 30, 2024
pulisher
Oct 20, 2024

The United States Gastroesophageal Reflux Disease Therapeutics Market Size & Outlook, 2030 - Grand View Research

Oct 20, 2024
pulisher
Oct 18, 2024

Outlook Therapeutics' (OTLK) Buy Rating Reiterated at BTIG Research - MarketBeat

Oct 18, 2024
pulisher
Oct 18, 2024

Outlook Therapeutics Participates in a Virtual Investor CEO Connect Segment - Marketscreener.com

Oct 18, 2024
pulisher
Oct 18, 2024

How the (OTLK) price action is used to our Advantage - Stock Traders Daily

Oct 18, 2024
pulisher
Oct 17, 2024

Outlook Therapeutics® Participates in a Virtual Investor CEO Connect Segment - GlobeNewswire

Oct 17, 2024
pulisher
Oct 16, 2024

Wet Age-Related Macular Degeneration Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers - The Globe and Mail

Oct 16, 2024
pulisher
Oct 14, 2024

Severe Acute Respiratory Syndrome (SARS) Therapeutics Market 2023 Outlook By Product, Trends and Forecast To (2024-2034) – IndiaPolitics.com - IndiaPolitics.com

Oct 14, 2024
pulisher
Oct 11, 2024

OUTLOOK ALERT: Bragar Eagel & Squire, P.C. is Investigating Outlook Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm - ForexTV.com

Oct 11, 2024
pulisher
Oct 11, 2024

ROSEN, A LEADING LAW FIRM, Encourages Sage Therapeutics, Inc. Investors to Secure Counsel Before Important - EIN News

Oct 11, 2024
pulisher
Oct 11, 2024

OUTLOOK ALERT: Bragar Eagel & Squire, P.C. is Investigating - GlobeNewswire

Oct 11, 2024
pulisher
Oct 10, 2024

Outlook Therapeutics Awaits Wet AMD Trial Results Of ONS-5010 - RTTNews

Oct 10, 2024
pulisher
Oct 05, 2024

OTLK DEADLINE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Outlook Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionOTLK - AsiaOne

Oct 05, 2024
pulisher
Oct 05, 2024

Outlook Therapeutics, Inc. (NASDAQ:OTLK) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat

Oct 05, 2024
pulisher
Oct 05, 2024

(OTLK) On The My Stocks Page - Stock Traders Daily

Oct 05, 2024
pulisher
Oct 04, 2024

A Glimpse Into The Expert Outlook On Halozyme Therapeutics Through 12 Analysts - Benzinga

Oct 04, 2024
pulisher
Oct 01, 2024

Outlook Therapeutics CFO buys $28.4k in company stock - Investing.com India

Oct 01, 2024
pulisher
Oct 01, 2024

Insider Buying: CFO Lawrence Kenyon Acquires Shares of Outlook T - GuruFocus.com

Oct 01, 2024
pulisher
Sep 30, 2024

Outlook Therapeutics CFO buys $28.4k in company stock By Investing.com - Investing.com Australia

Sep 30, 2024
pulisher
Sep 30, 2024

Neumora Therapeutics' SWOT analysis: navacaprant's potential lifts stock outlook - Investing.com

Sep 30, 2024
pulisher
Sep 24, 2024

Great Point Partners LLC Raises Position in Outlook Therapeutics, Inc. (NASDAQ:OTLK) - Defense World

Sep 24, 2024
pulisher
Sep 24, 2024

(OTLK) Investment Analysis - Stock Traders Daily

Sep 24, 2024
pulisher
Sep 24, 2024

Great Point Partners LLC Grows Stake in Outlook Therapeutics, Inc. (NASDAQ:OTLK) - MarketBeat

Sep 24, 2024
pulisher
Sep 24, 2024

Pliant Therapeutics, Inc. (NASDAQ:PLRX) Shares Sold by First Light Asset Management LLC - Defense World

Sep 24, 2024
pulisher
Sep 23, 2024

Checking in on Outlook Therapeutics Inc (OTLK) after recent insiders movement - Knox Daily

Sep 23, 2024
pulisher
Sep 23, 2024

Investor’s Toolkit: Key Ratios for Assessing Outlook Therapeutics Inc (OTLK)’s Performance - The Dwinnex

Sep 23, 2024
pulisher
Sep 23, 2024

A year in review: Outlook Therapeutics Inc (OTLK)’s performance in the last year - US Post News

Sep 23, 2024
pulisher
Sep 16, 2024

Outlook Therapeutics® to Participate in the Virtual Investor Closing Bell Series - ForexTV.com

Sep 16, 2024
pulisher
Sep 13, 2024

Outlook Therapeutics® Participates in the 2nd Annual Chardan Virtual Ophthalmology Conference Series - GlobeNewswire

Sep 13, 2024
pulisher
Sep 12, 2024

OTLKOutlook Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan

Sep 12, 2024
pulisher
Sep 11, 2024

Outlook Therapeutics Inc (OTLK) Becoming More Attractive for Investors - Knox Daily

Sep 11, 2024
pulisher
Sep 11, 2024

UK Asthma Therapeutics Market Size & Outlook, 2023-2030 - Grand View Research

Sep 11, 2024
pulisher
Sep 10, 2024

Private equity firms are Outlook Therapeutics, Inc.'s (NASDAQ:OTLK) biggest owners and were rewarded after market cap rose by US$30m last week - Simply Wall St

Sep 10, 2024
pulisher
Sep 10, 2024

Outlook Therapeutics, Inc. (NASDAQ:OTLK) Receives Average Rating of "Buy" from Brokerages - MarketBeat

Sep 10, 2024
pulisher
Sep 05, 2024

Outlook Therapeutics Inc [OTLK] Shares Jump Approximately 62.65% Over the Year - Knox Daily

Sep 05, 2024
pulisher
Sep 05, 2024

Iovance Therapeutics: Historic Product, Tough Commercial Outlook - Seeking Alpha

Sep 05, 2024
pulisher
Sep 04, 2024

Outlook Therapeutics completes NORSE EIGHT enrollment - Investing.com

Sep 04, 2024
pulisher
Sep 04, 2024

Outlook Therapeutics® Announces Completion of Enrollment in NORSE EIGHT Clinical Trial - GlobeNewswire

Sep 04, 2024

Finanzdaten der Outlook Therapeutics Inc-Aktie (OTLK)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Outlook Therapeutics Inc-Aktie (OTLK) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
Haddadin Yezan Munther
Director
Mar 28 '24
Buy
11.82
1,882
22,242
5,049
Evanson Jeff
CHIEF COMMERCIAL OFFICER
Mar 07 '24
Buy
0.42
62,484
26,243
808,459
$18.98
price up icon 1.80%
$70.68
price down icon 0.42%
$38.38
price up icon 3.49%
$369.83
price up icon 1.48%
$196.58
price up icon 0.88%
$102.64
price up icon 0.27%
Kapitalisierung:     |  Volumen (24h):